SARMs and the U.S. Marine Corps: Policy, Drug Testing, and Health Risks Explained

Key takeaways

Are SARMs banned in the Marine Corps and the wider military?

Yes. Selective androgen receptor modulators (SARMs) are unapproved drugs, and Operation Supplement Safety (OPSS), the Department of Defense's official program on supplement safety, states plainly that use of SARMs is dangerous with known health risks and that they are prohibited for use by DoD. A Marine Corps Community Services (MCCS) article distributing this OPSS guidance to Marines specifically warns that SARMs pose significant health and readiness risks and that OPSS strongly advises against using such products.

This prohibition is written into binding policy, not just advisory guidance. DoD Instruction 6130.06, Use of Dietary Supplements in the DoD, prohibits servicemembers from using dietary supplements containing ingredients listed on the DoD Prohibited Dietary Supplement Ingredients List unless specifically authorized by a military medical provider. The instruction anticipates enforcement through command channels, and service members can be prosecuted under the Uniform Code of Military Justice for using dietary supplements containing listed substances, subject to limited exceptions such as authorized medical use.

Because SARMs are not scheduled controlled substances under federal drug law, they sit in a different legal category than anabolic steroids, but that does not make them permissible. Military legal commentary on this issue notes that while SARMs may not be controlled substances like anabolic steroids, their use by service members is still prohibited, and DoD Instruction 6130.06 states that service members will not use products containing ingredients on the OPSS prohibited list unless authorized, with commanders able to treat violations as a failure to obey a lawful general order or regulation under UCMJ Article 92.

One caveat on precision here: some secondary sources describe MK-677 (Ibutamoren) as a SARM that appears on the prohibited list. OPSS's own consumer guidance is more precise and warns that Ibutamoren/MK-677, along with Cardarine/GW-501516 and YK-11, are experimental drugs sometimes marketed as SARMs but are not actually SARMs. Regardless of that classification detail, OPSS confirms these compounds are separately prohibited for DoD use.

Does the military drug test for SARMs?

Routine, random urinalysis in the Marine Corps and other services is built around a standard panel and does not automatically screen for SARMs. In addition to that standard panel, service members are also subject to testing for other performance-enhancing drugs under DoD Instruction 1010.16, specifically substances in categories S1, S2, and S4 of the World Anti-Doping Agency (WADA) Prohibited List, which cover steroids, SARMs, peptides, growth hormones, and hormone or metabolic modulators such as aromatase inhibitors. This DoD-wide testing authority under DoDI 1010.16 applies to the Marine Corps along with the other services.

Targeted, expanded PED testing programs have grown in recent years, though the clearest public examples so far involve special operations components rather than the Marine Corps generally. In September 2023, Naval Special Warfare Command announced it would begin forcewide, random urinalysis testing for performance-enhancing drugs starting November 1, under expanded authority granted by the Navy and the Department of Defense, after an investigation following the death of a SEAL candidate flagged PED use as a concern. At the time of that announcement, Army Special Operations Command said it would soon follow suit with its own expanded testing, though without a confirmed start date. Public reporting reviewed for this article did not identify an equivalent, formally announced forcewide PED testing expansion specific to the Marine Corps; that does not mean targeted testing cannot happen, only that the high-profile forcewide programs reported to date have centered on Navy and Army special operations units.

Separately from any forcewide expansion, DoD policy already supports a zero-tolerance framework backed by testing for cause or during investigations, meaning a command with credible suspicion, such as a tip, a report of suspicious purchases, or a health event linked to supplement use, can request specialized, targeted testing for steroids or SARMs even where the standard panel would not catch them.

In practice, this means a Marine's ordinary random urinalysis is unlikely to flag SARM use unless the command has specifically requested an expanded or targeted panel. However, this should not be read as evidence that SARM use is tolerated. Policy prohibits the substances themselves, not merely a positive lab result, so possession, purchase, or use can be charged independently of any urinalysis outcome.

What happens if a Marine is caught using or possessing SARMs?

Because SARMs appear on the DoD Prohibited Dietary Supplement Ingredients List, using a product containing them can be charged as a failure to obey a lawful general order or regulation under UCMJ Article 92, and DoD Instruction 6130.06 explicitly anticipates that service members can be prosecuted under the UCMJ for this, subject to limited exceptions such as authorized medical use.

Consequences described in military-focused legal commentary range from administrative actions up to separation from service, and unintentional exposure to a prohibited compound, including through a contaminated dietary supplement, may still result in administrative or disciplinary action, including separation. The specific outcome in any case depends on the command, the facts, and the Marine's record, and general courts-martial are a possibility under Article 92 in more serious circumstances, though the precise threshold is set by the facts of each case rather than by a fixed rule.

Marines with questions about a specific case, including questions about disclosing prior supplement use, are better served by consulting a defense counsel or JAG resource than a scientific reference site, since case-specific legal advice depends on facts that this article cannot address.

Why is the Marine Corps concerned about SARMs specifically?

The concern combines legal status, health risk, and readiness. On legal status, the FDA states that these bodybuilding products, which often contain SARMs, have not been approved by the FDA, and that although they are generally marketed as dietary supplements, they are not dietary supplements but unapproved drugs that the FDA has not reviewed for safety and effectiveness. According to OPSS, no SARM has been approved by the FDA for any medical use.

On health risk, the FDA states that life-threatening reactions, including liver injuries requiring hospitalization, have occurred in people taking products containing SARMs, and that SARMs also have the potential to cause increased risk of heart attack or stroke, psychosis or hallucinations, sleep disturbances, sexual dysfunction, liver injury and acute liver failure, infertility, pregnancy miscarriage, and testicular shrinkage.

On readiness, the Marine Corps' own MCCS/OPSS guidance frames SARMs in exactly these terms, warning that they pose significant health and readiness risks, and separately notes that SARM use might interfere with the body's natural testosterone release. A Marine who develops acute liver injury, a cardiovascular event, or a musculoskeletal injury is not deployable, which is a direct readiness cost. A 2023 systematic review of SARM safety in healthy adults found case reports of drug-induced liver injury, Achilles tendon rupture, and rhabdomyolysis among recreational users, harms that are especially relevant to a population that trains under heavy physical load.

What does the scientific evidence say about SARM safety?

The evidence base combines early-phase clinical trials in patients with muscle-wasting conditions with a growing pool of case reports describing harm in recreational users, and the two bodies of evidence do not always point the same direction. A 2023 systematic review identified 33 studies, including 15 case reports or case series and 18 clinical trials, covering a total of 2,136 patients, of whom 1,447 were exposed to a SARM. Among the case reports, the review found 15 cases of drug-induced liver injury, one case of Achilles tendon rupture, one case of rhabdomyolysis, and one case of mild reversible liver enzyme elevation. Elevated liver enzymes were also commonly reported in clinical trials, averaging about 7.1 percent of participants exposed to a SARM across trials, and two individuals exposed to the investigational SARM GSK2881078 in a clinical trial developed rhabdomyolysis.

Individual published case reports illustrate this pattern. A 2023 case report described a 22-year-old man who developed worsening jaundice, nausea, and pruritus after reportedly taking RAD-140 for 16 weeks, with liver testing and imaging consistent with drug-induced cholestatic-pattern liver injury. A 2024 case report described drug-induced liver injury, presenting with jaundice and weight loss, in a 52-year-old man following three months of high-dose LGD-4033 (Ligandrol) use. The NIH's LiverTox resource maintains a dedicated monograph on SARMs, describing them as synthetic drugs designed to bind androgen receptors with tissue-selective activity intended to produce fewer androgenic effects on organs such as the liver and heart than anabolic steroids, a design goal that the hepatotoxicity case reports call into question in practice.

The strength of this evidence should be graded honestly. Controlled clinical trials of individual SARM candidates in patients with cancer cachexia or muscle wasting have generally been short in duration and conducted in small samples, and they do not reflect the doses, durations, product purity, or polydrug use patterns typical of unsupervised recreational use. The case report literature is not randomized or controlled and cannot establish causation with certainty in every instance, since contaminated or mislabeled products and concurrent substance use often confound individual reports. Taken together, this amounts to a moderate signal for hepatotoxicity that recurs across independent reports, alongside weaker and more preliminary evidence for cardiovascular and reproductive harms, and essentially no long-term safety data in humans.

Because no SARM has completed the clinical trial process required for FDA approval, there is no dataset establishing a safe dose, a safe duration of use, or a reliable safety margin for otherwise healthy adults. That absence of safety data, not just the legal status of these compounds, is a central reason regulatory and military authorities treat them as unacceptable for use outside a monitored clinical trial.

What is the FDA's official position on SARMs?

The FDA describes SARMs as chemical substances that mimic the effects of testosterone and anabolic steroids. Although these products are generally marketed as dietary supplements, the FDA states they are not dietary supplements but unapproved drugs that the agency has not reviewed for safety or effectiveness, and it continues to warn consumers, including through a 2025 consumer alert, about bodybuilding products containing SARMs.

The agency has issued warning letters to multiple companies selling SARMs-containing products, including a December 2025 warning letter to a company whose SARM-marketed products the FDA determined were intended as drugs for human use, and it has stated that life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs, along with an increased risk of heart attack and stroke.

The FDA has also supported criminal enforcement. In one Department of Justice case, a North Carolina supplement company owner pleaded guilty to unlawfully distributing SARMs and other FDA-unapproved substances, including Ostarine (MK-2866), Ligandrol (LGD-4033), and Testolone (RAD-140), with prosecutors citing a 2017 FDA warning letter stating that SARMs have been linked to life-threatening reactions including liver toxicity and an increased risk of heart attack and stroke. Similar guilty pleas have followed in other federal cases involving SARM distribution.

The FDA's more recent consumer-facing warnings caution against social media posts that target teenagers and young adults with claims that SARMs offer a quick or easy way to improve physical appearance or athletic performance, noting that these products are often sold without warning labels or are marketed as being for research purposes only despite being intended for human use.

Frequently asked

References